An Amibitious Couple's Blog Experiment

Jim Tananbaum: A Top 100 Investor with an Impressive Health-Care Track Record

Recognized in the Forbes Midas Top 100 list of investors in 2017, Jim Tananbaum has built a reputation as one of today’s leading financial innovators in the cutting-edge bio-tech space.


Having earned an undergraduate degree in mathematics from Yale University, an M.S. from the Massachusetts Institute of Technology and both an MBA and MD from Harvard University has equipped Jim Tananbaum with more than enough academic credential to stand out as a top leader in his indiustry.


In a report by Insider Monkey, as founder and CEO of Foresite Capital Management, which provides growth capital to emerging health-care leaders that deliver disruptive products and services, Jim Tananbaum has overseen more than 21 successes in bio-tech firms such as Amira Pharmaceuticals, 10x Genomics, Jazz Pharmaceuticals, Amerigroup and Intarcia Therapeutics, for which he received Midas Top 100 recognition.


Foresite Capital builds upon Tananbaum’s long list of accomplishments including his founding of GelTex Pharmaceuticals, which was acquired in 1998 for $1.6 billion and trades on the NASDAQ: GENZ, as well as co-founder of Theravance, Inc., which also trades on NASDAQ:INVA and its spin-off NASDAQ:TBPH, both divisions of Theravance having a combined market capitalization of $3.2 billion. He also previously held positions as a founding partner at Prospect Ventures and as a partner at Sierra Ventures, where he demonstrated his acumen in health-care investing. You can visit Crunchbase to know more.


He describes his talent for investing as being a mix of risk-taking and performing extensive due diligence, a combination that has resulted in multiple-wins significantly more times than losses.


A believer in the value of people, Tananbaum offers that synergy is a key factor in building the right team. He relates the importance of synergy between team members, which he compares as producing a 1 + 1 = 3 level of performance versus a non-synergistic combination of people that results in dramatically poorer outputs than what would otherwise be produced by those same team members individually, ex., 1 + 1 = ½ in that case. Check out LinkedIn for more info.


According to Business Wire, working in the overlapping areas of innovative health-care solution providers and investment offers Tananbaum the opportunity to pursue his passion of working with entrepreneur leaders and academicians and at the same time being part of the exciting potential that deep learning is demonstrating in the field of medicine.


Leave a comment for: "Jim Tananbaum: A Top 100 Investor with an Impressive Health-Care Track Record"

Tag Cloud